Phesgo (fixed-dose combination of pertuzumab and trastuzumab) approved for use in in EU for HER2-positive breast cancer

This subcutaneous injection of a combination of two monoclonal antibodies can be administered in eight minutes, as compared to 150 minutes for the sequential infusions of these two drugs when given separately.

Source:

Biospace Inc.